
Tourmaline Bio Welcomes Dr. Clay Siegall as Chairman of the Board: A Promising Step Towards Advancements in Biotechnology
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board New York, Dec. 14, 2023 (GLOBE NEWSWIRE) Tourmaline Bio, Inc. (“Tourmaline”) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that Clay Siegall, PhD, has been appointed as…